Article Text

Download PDFPDF
A randomized phase III trial of adjuvant chemotherapy versus concurrent chemoradiotherapy for postoperative cervical cancer: Japanese Gynecologic Oncology Group study (JGOG1082)
  1. Akiko Furusawa1,
  2. Munetaka Takekuma2,
  3. Keita Mori3,
  4. Tomoka Usami4,
  5. Eiji Kondo5,
  6. Shin Nishio6,
  7. Koji Nishino7,
  8. Yuichiro Miyamoto8,
  9. Ryoichi Yoshimura9,
  10. Miho Watanabe10,
  11. Mikio Mikami11 and
  12. Takayuki Enomoto7
  1. 1 Department of Gynecology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Bunkyo-ku, Japan
  2. 2 Department of Gynecology, Shizuoka Cancer Center Hospital, Sunto-gun, Shizuoka, Japan
  3. 3 Department of Clinical Research Center, Shizuoka Cancer Center Hospital, Sunto-gun, Shizuoka, Japan
  4. 4 Department of Obstetrics and Gynecology, Ehime University, Matsuyama, Ehime, Japan
  5. 5 Department of Obstetrics and Gynecology, Mie University, Tsu, Mie, Japan
  6. 6 Department of Obstetrics and Gynecology, Kurume University School of Medicine, Kurume, Fukuoka, Japan
  7. 7 Department of Obstetrics and Gynecology, Niigata University, Niigata, Niigata, Japan
  8. 8 Department of Obstetrics and Gynecology, The University of Tokyo, Bunkyo-ku, Tokyo, Japan
  9. 9 Department of Radiology, Tokyo Medical and Dental University, Bunkyo-ku, Tokyo, Japan
  10. 10 Department of Radiology, Chiba University, Chiba, Chiba, Japan
  11. 11 Department of Obstetrics and Gynecology, Tokai University, School Of Medicine, Isehara, Japan
  1. Correspondence to Dr Munetaka Takekuma, Department of Gynecology, Shizuoka Cancer Center Hospital, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan; m.takekuma{at}scchr.jp

Abstract

Background The standard treatment for stage IB–IIB cervical cancer is radiotherapy or radical hysterectomy; after radical hysterectomy, adjuvant concurrent chemoradiotherapy is recommended for patients with high risk factors. However, adjuvant concurrent chemoradiotherapy can cause severe gastrointestinal and urinary toxicity.

Primary Objective To assess whether postoperative adjuvant chemotherapy is not inferior to adjuvant concurrent chemoradiotherapy for overall survival in patients with high risk cervical cancer.

Study Hypothesis Adjuvant chemotherapy is not inferior to adjuvant concurrent chemoradiotherapy for overall survival and will reduce severe toxicities.

Trial Design Patients with high risk factors after radical hysterectomy will be randomized 1:1 to receive adjuvant concurrent chemoradiotherapy or adjuvant chemotherapy. Treatment will be started within 6 weeks of surgery. The concurrent chemoradiotherapy group will receive whole pelvis irradiation (50.4 Gy) and cisplatin (40 mg/m2/week). The chemotherapy group will receive paclitaxel (175 mg/m2) plus cisplatin (50 mg/m2) or carboplatin (AUC=6) every 3 weeks for six cycles.

Major Inclusion/Exclusion Criteria Patients with high risk stage IB–IIB cervical cancer (squamous cell carcinoma, adenocarcinoma, and adenosquamous cell carcinoma) who underwent radical hysterectomy are eligible for the study. High risk is defined as the presence of pelvic lymph node metastasis and/or parametrial invasion.

Primary Endpoint The primary endpoint is overall survival.

Sample Size 250 patients in total are required.

Estimated Dates for Completing Accrual This study began in November 2019, and 250 patients will be accrued within 5 years.

Trial Registration Number The study has been registered with the Japan Registry of Clinical Trials (jRCTs041190042).

  • cervical cancer
  • postoperative care

Statistics from Altmetric.com

Footnotes

  • Contributors AF is the principal investigator of the study. MT is chairman of the Japanese Gynecologic Oncology Group (JGOG) cervical cancer committee. TU, EK, SN, KN, YM, and MM are members of the JGOG cervical cancer committee. RY and MW are members of the JGOG radiotherapy committee. KM is a biostatistician for this study. TE is chairman of the JGOG.

  • Funding This study was funded by the Japan Agency for Medical Research and Development.

  • Competing interests None declared.

  • Patient consent for publication Not required.

  • Ethics approval The protocol and amendments were approved by the Central Review Board of Shizuoka Cancer Center (Shizuka Cancer Center Certified Review Board).

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Data availability statement Data are available in a public, open access repository.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.